Literature DB >> 10951403

In situ expression of fibrogenic growth factors and their receptors in biliary atresia: comparison between early and late stages.

A Faiz Kabir Uddin Ahmed1, H Ohtani, M Nio, N Funaki, D Iwami, S Kumagai, E Sato, H Nagura, R Ohi.   

Abstract

Progressive fibrosis, despite successful surgical treatment, is one of the serious complications of biliary atresia. To understand the mechanism of this fibrosis, the in situ expression of fibrogenic growth factors (TGF-beta and PDGF) and their corresponding receptors was studied by immunohistochemistry using frozen sections. The results were compared between the early (n=12) and late (n=6) stages. The early stage was characterized by abundant expression of all ligands and receptors, together with type I procollagen (PC-I). The major cellular sources were activated fibroblasts/myofibroblasts distributed mostly in the portal tracts. Macrophages also expressed all the ligands and the receptors, but to a lesser degree. Bile duct cells strongly expressed TGF-beta RI and RII and PDGF AA and BB, but focally expressed TGF-beta. All of these decreased in the late stage of biliary atresia. These results suggest that TGF-beta and PDGF play important roles in the fibrogenesis of biliary atresia, especially in its early stage, acting either by autocrine or paracrine mechanisms involving activated fibroblasts/myofibroblasts, bile duct cells, and macrophages. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951403     DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH657>3.0.CO;2-J

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

1.  Hypoxia-inducible factor activation in myeloid cells contributes to the development of liver fibrosis in cholestatic mice.

Authors:  Bryan L Copple; Sophia Kaska; Callie Wentling
Journal:  J Pharmacol Exp Ther       Date:  2012-01-23       Impact factor: 4.030

2.  Hedgehog activity, epithelial-mesenchymal transitions, and biliary dysmorphogenesis in biliary atresia.

Authors:  Alessia Omenetti; Lee M Bass; Robert A Anders; Maria G Clemente; Heather Francis; Cynthia D Guy; Shannon McCall; Steve S Choi; Gianfranco Alpini; Kathleen B Schwarz; Anna Mae Diehl; Peter F Whitington
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

Review 3.  PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer.

Authors:  Alexander Kikuchi; Satdarshan Pal Monga
Journal:  Gene Expr       Date:  2015

4.  Squamous cell carcinoma of the lung with highly proliferating fibromatosis-like stroma: a rare phenomenon.

Authors:  Shogo Tajima; Yusuke Takanashi; Kenji Koda
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic Kupffer cells.

Authors:  Bryan L Copple; Shan Bai; Jeon-Ok Moon
Journal:  Hepatol Res       Date:  2010-04-14       Impact factor: 4.288

6.  Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic hepatocytes.

Authors:  Bryan L Copple; Juan J Bustamante; Timothy P Welch; Nam Deuk Kim; Jeon-Ok Moon
Journal:  Liver Int       Date:  2009-03-19       Impact factor: 5.828

Review 7.  Role of Hypoxia-Inducible Factors in the Development of Liver Fibrosis.

Authors:  Katherine J Roth; Bryan L Copple
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-09-25

8.  PDGFA gene rs9690350 polymorphism increases biliary atresia risk in Chinese children.

Authors:  Fei Liu; Jixiao Zeng; Deli Zhu; Xiaogang Xu; Menglong Lan; Mengmeng Wang; Jinglu Zhao; Huimin Xia; Yan Zhang; Ruizhong Zhang
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

9.  TGF-β Signaling Plays a Pivotal Role During Developmental Biliary Atresia in Sea Lamprey (Petromyzon marinus).

Authors:  Yu-Wen Chung-Davidson; Jianfeng Ren; Chu-Yin Yeh; Ugo Bussy; Belinda Huerta; Peter Joseph Davidson; Steven Whyard; Weiming Li
Journal:  Hepatol Commun       Date:  2019-12-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.